{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:41:39Z","timestamp":1768887699236,"version":"3.49.0"},"reference-count":26,"publisher":"Impact Journals, LLC","issue":"41","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,12,22]]},"DOI":"10.18632\/oncotarget.5833","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T13:34:54Z","timestamp":1445952894000},"page":"44049-44056","source":"Crossref","is-referenced-by-count":4,"title":["Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for treating relapsed or refractory non-Hodgkin's lymphoma"],"prefix":"10.18632","volume":"6","author":[{"given":"Hang","family":"Yang","sequence":"first","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhan","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Clinical Trial Center, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-Wen","family":"Bi","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan-Pan","family":"Liu","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Clinical Trial Center, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben-Yan","family":"Zou","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Nursing Department, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Qi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2015,10,17]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: rationale and promise","volume":"4","author":"Cantley","year":"2003","journal-title":"Cancer Cell"},{"key":"2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"key":"3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Cantley","year":"2006","journal-title":"Nat Rev Genet"},{"key":"4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Zhao","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"11168","DOI":"10.18632\/oncotarget.2584","article-title":"Targeted PI3K\/AKT\/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience","volume":"5","author":"Fu","year":"2014","journal-title":"Oncotarget"},{"key":"7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.18632\/oncotarget.1468","article-title":"A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma","volume":"5","author":"Hong","year":"2014","journal-title":"Oncotarget"},{"key":"8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Engelman","year":"2010","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-12-0714","article-title":"A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors","volume":"18","author":"Kurzrock","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.ejca.2012.06.027","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K\/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies","volume":"48","author":"Garlich","year":"2012","journal-title":"Eur J Cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors","volume":"21","author":"Wu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature04694","article-title":"Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation","volume":"441","author":"Vanhaesebroeck","year":"2006","journal-title":"Nature"},{"key":"13","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Siu","year":"2012","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","article-title":"The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia","volume":"117","author":"Johnson","year":"2011","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Ulrich","year":"2011","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Vanhaesebroeck","year":"2002","journal-title":"Science"},{"key":"17","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.4049\/jimmunol.0900432","article-title":"Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses","volume":"183","author":"Gold","year":"2009","journal-title":"J Immunol"},{"key":"18","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mds011","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors","volume":"23","author":"Baselga","year":"2012","journal-title":"Ann Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Cavazos","year":"2012","journal-title":"Clin Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/cas.12444","article-title":"Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors","volume":"105","author":"Doi","year":"2014","journal-title":"Cancer Sci"},{"key":"21","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Johnson","year":"2014","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Wagner-Johnston","year":"2014","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Baselga","year":"2012","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Hiddemann","year":"1999","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.bjc.6604444","article-title":"Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer","volume":"99","author":"Nutting","year":"2008","journal-title":"Br J Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/annonc\/mdn364","article-title":"Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels","volume":"19","author":"Vokes","year":"2008","journal-title":"Ann Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T14:20:40Z","timestamp":1653402040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,17]]},"references-count":26,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2015,12,22]]}},"alternative-id":["5833","26510909"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5833","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,17]]}}}